Top Oligonucleotide Synthesis Companies

Oligonucleotide Synthesis Market size was valued at USD 7.3 Billion in 2023 and is poised to grow from USD 8.57 Billion in 2024 to USD 30.88 Billion by 2032, growing at a CAGR of 17.4% during the forecast period (2025-2032).

Investing in the development of oligonucleotide synthesis for different disease indications should remain the prime focus of all companies. Reducing the costs of synthesis will be a major area of interest for all oligonucleotide synthesis providers to improve their profitability. Utilizing supportive government initiatives and funding to maximize R&D scope will also be a popular strategy for oligonucleotide synthesis market players in the future.  'Danaher Corporation ', 'Thermo Fisher Scientific Inc. ', 'Merck KGaA ', 'Eurofins Scientific ', 'Agilent Technologies, Inc. ', 'Kaneka Corporation ', 'Azenta, Inc. ', 'Sarepta Therapeutics, Inc. ', 'AstraZeneca ', 'Astellas Pharma Inc. ', 'Jazz Pharmaceuticals PLC ', 'Nippon Shinyaku, Co. Ltd. (NS Pharma, Inc.) ', 'Ionis Pharmaceuticals, Inc. ', 'Novartis AG ', 'OligoMaker ApS (Part of TAG Copenhagen A/S) ', 'Biolegio BV ', 'Biolytic Lab Performance, Inc. ', 'Bio-Synthesis, Inc. ', 'Creative Biogene ', 'Reprocell, Inc.'

Oligonucleotides play a key role in diagnostic tools such as PCR, qPCR, and next-generation sequencing (NGS) and demand for early diagnostics is increasing rapidly. This factor is projected to create new opportunities for oligonucleotide synthesis market growth going forward. 

Use of AI and Automation: Automation and artificial intelligence are being integrated into oligonucleotide synthesis processes, to enhance the accuracy and scalability of the process. Automated synthesizers and AI-driven design tools are projected to be highly popular as they can assist in cost reduction as well.  

North America is projected to account for a dominant oligonucleotide synthesis market share. The presence of a strong medical research infrastructure, supportive government funding for research, and rising use of genetic treatments are helping this region maintain its high market share. The United States and Canada are estimated to be the leading markets in this region as incidence of chronic diseases rises in these countries. The presence of leading pharmaceutical and biotechnology companies will also promote the demand for oligonucleotide synthesis in this region.